Spirit Scientific Co., Ltd.
TTPEX:779043.90
TWD
0.00
(0.00%)
Spirit Scientific Co., Ltd.
TPEX:7790
(Taipei Exchange)
Recent
price
43.90
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.- Similar Companies
- Business
- Spirit Scientific Co., Ltd. is a Taiwan-based biotechnology company specializing in regenerative medicine, lyophilized biomaterials, and advanced cell processing technologies. Founded in 2020 and headquartered in New Taipei City, Taiwan, the company utilizes a standardized regenerative medicine Biofoundry platform powered by its proprietary Bio Material Lyophilized Technology (BMLT) to convert delicate biological substances into room-temperature-storable, dosage-controlled, and high-stability powdered preparations. The company offers a structured portfolio of products and contract services across clinical regenerative therapies, aesthetic medicine, and biomedical manufacturing. Its core offerings include: Platelet Lyophilized Treatment (PLT), an autologous platelet-derived growth factor therapeutic service delivering quantifiable, multi-dose powdered formulations from a single blood collection for tissue repair and regenerative therapy; PLT Hydraglow, a specialized topical post-treatment repair hydrogel formulation combining lyophilized bio-actives with hyaluronic acid; autologous platelet-derived exosome lyophilization services for clinical skin regeneration, tissue healing, and hair restoration applications; Contract Development and Manufacturing Organization (CDMO) services providing standardized cell processing, lyophilization process development, and quality testing under its dedicated SSLab infrastructure; and orthopedic medical devices, including the Vessel-X Bone Filling Containment System for minimally invasive surgical management of osteoporotic vertebral compression fractures. Spirit Scientific primarily serves healthcare providers, clinical specialists, and biopharmaceutical institutions across medical aesthetics, orthopedics, rehabilitation, sports medicine, dermatology, gynecology, and urology, supporting a commercial network of over 1,700 medical institutions. In recent corporate developments, Spirit Scientific completed its initial public listing on the Emerging Stock Board of the Taipei Exchange under ticker 7790 in December 2024. In late 2025, the company obtained overseas specific cell processing facility accreditation from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) under the Ministry of Health, Labour and Welfare (MHLW) for its Xizhi manufacturing facility, marking Taiwan's first platelet and biomaterial lyophilization site to achieve PMDA compliance. To accelerate overseas commercialization, the company established its wholly owned subsidiary, Spirit Scientific Japan Co., Ltd., and initiated trial operations of its specialized processing laboratory in Ariake, Tokyo. Furthermore, Spirit Scientific broadened its technological capabilities into exosome therapeutics through strategic exchanges and cross-border partnerships with regional regenerative medicine leaders, including Japan-based CellSource, while actively extending its lyophilized biomaterial platforms into cosmeceutical and skincare active ingredient markets.